Exploitation of parasite derived antigen in therapeutic success of human cutaneous leishmaniasis in Brazil

Mem Inst Oswaldo Cruz. 1994 Jul-Sep;89(3):479-83. doi: 10.1590/s0074-02761994000300034.

Abstract

In a complete study in 25 patients with American cutaneous leishmaniasis, caused by Leishmania braziliensis complex, immunotherapeutic efficacy of parasite derived antigen (94-67 KD) has been compared to antimonial therapy. Additionally, to delineate the mechanism of therapeutic success, microscopical features of immune response in active lesions and healed or non-healed lesions following therapy were analyzed. The results showed that cure rates in immunotherapy and chemotherapy were equal (> 83%). The immunohistochemical changes in two therapeutic groups were also largely similar. The analysis of humoral and cellular immune response suggest that appropriate stimulation of T helper cells in the lesion site, in association with one or more cytokines, play a key role in the healing process.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Animals
  • Antigens, Bacterial
  • Antigens, Protozoan / immunology
  • Antigens, Protozoan / therapeutic use*
  • Brazil
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immunotherapy*
  • Leishmania braziliensis / immunology*
  • Leishmaniasis, Cutaneous / immunology
  • Leishmaniasis, Cutaneous / therapy*
  • Macrophages / immunology
  • Male
  • Middle Aged
  • T-Lymphocytes / immunology

Substances

  • Antigens, Bacterial
  • Antigens, Protozoan